Lenacapavir Rollout Halted in Pretoria Due to Shortages and Readiness Issues Pretoria, South Africa — The much-anticipated rollout of Lenacapavir, a long-acting HIV prevention drug, has encountered unexpected setbacks in parts of Pretoria, leaving patients without access to the life-saving medication.
The Gauteng Department of Health commenced the phased rollout of Lenacapavir on June 8, 2026, at the Zone 7 sports ground in Pretoria.
However, within the first week, women in Gauteng reported shortages of injectables and implants at various clinics, raising concerns about the drug’s availability and the government’s readiness to implement the program.
The introduction of Lenacapavir is a significant step forward in the fight against HIV/AIDS in South Africa, which has been at the forefront of the epidemic.
The country has been implementing various initiatives, including adolescent and youth — friendly services and support from PEPFAR (President’s Emergency Plan for AIDS Relief). Despite these efforts, the challenges faced in the rollout of Lenacapavir underscore the complexities involved in ensuring equitable access to essential healthcare services.
Health — e News has reported on the discrepancies in the rollout of Lenacapavir across different clinics, highlighting the difficulties patients are experiencing.
The Gauteng ANC on Instagram, however, presented a positive perspective on the Gauteng Department of Health’s efforts to introduce Lenacapavir, suggesting it as a significant step forward in HIV prevention.
The Gauteng Department of Health’s initiative to start the rollout of Lenacapavir was confirmed by the Gauteng ANC on Instagram, but the rollout has not been without its problems.
Women in parts of Gauteng have reported shortages of injectables and the implant, indicating that the supply chain may not be as robust as initially thought. This has led to patients being turned away, a situation that is unacceptable in a country that has made significant strides in combating HIV/AIDS.
According to a report by Gilead Sciences, the manufacturer of Lenacapavir, the drug’s pricing and patents have been a point of contention.
The company has licensing agreements with six generic manufacturers covering 120 low-income countries, but the high cost of the drug in high-income settings remains a barrier to access in low- and middle-income countries (LMICs), including South Africa.
The Gauteng Health Department has been active on social media, engaging with the public and addressing concerns.
However, the reality on the ground is that patients are facing shortages, and the department’s response to these issues is critical.
The situation in Pretoria serves as a cautionary tale for the rest of the country and the world, as the rollout of such a significant medication is fraught with challenges that require careful planning and execution.
The Gauteng Department of Health must address the shortages and readiness issues immediately to ensure that patients in Pretoria and beyond have access to the medication they need.
The Department must also provide a clear explanation of the reasons behind the setbacks and outline a plan to rectify the situation.
Only through transparency and accountability can the trust of the public be restored, and the fight against HIV/AIDS in South Africa can continue to move forward.
The challenges faced in the rollout of Lenacapavir in Pretoria are a stark reminder of the complexities involved in implementing large — scale healthcare initiatives.
As South Africa continues to grapple with the HIV/AIDS epidemic, it is essential that the government and its partners work together to ensure that all citizens have access to the healthcare services they need to live healthy, productive lives.
*Additional reporting by ImNews | Sources consulted: 5*
—
This original article was produced by the ImNews editorial team
Source: Google News v2
